Soleno Therapeutics price target raised to $115 from $108 at Stifel

Stifel raised the firm’s price target on Soleno Therapeutics (SLNO) to $115 from $108 and keeps a Buy rating on the shares after having conducted a survey of 20 physicians. The firm’s survey work found demand is “significant” and widespread, according to the analyst, who calls the results “highly favorable” for Vykat and broadly supportive of the Soleno bull case. The firm came away from its work more confident in its view that Vykat should track with other “very strong” initial rare disease drug launches and it now models about $2.5B in peak sales.